Brainstorm Cell Therapeutics Inc  

(Public, NASDAQ:BCLI)   Watch this stock  
Find more results for OTC:BCLI
3.85
0.00 (0.00%)
Dec 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.79 - 4.18
52 week 2.03 - 5.70
Open 3.99
Vol / Avg. 0.00/85,445.00
Mkt cap 58.83M
P/E     -
Div/yield     -
EPS -0.60
Shares 15.28M
Beta 0.61
Inst. own 11%
Jan 5, 2015
Brainstorm Cell Therapuetics Inc to Discuss Final Phase 2a Trial of NurOwn in ALS Conference Call - 8:30AM EST - Add to calendar
Nov 13, 2014
Q3 2014 Brainstorm Cell Therapuetics Inc Earnings Call - Webcast
Nov 13, 2014
Q3 2014 Brainstorm Cell Therapuetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -81.18% -99.33%
Return on average equity -99.59% -145.78%
Employees 14 -
CDP Score - -

Address

34TH FLOOR, 605 THIRD AVENUE
NEW YORK, NY 10158
United States - Map
+1-646-6663188 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Brainstorm Cell Therapeutics Inc. (Brainstorm) is a biotechnology company developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS), and Parkinson�s disease (PD). These diseases have limited treatment options and as such represent unmet medical needs. The Company�s NurOwn technology is based on a differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells, MSC-NTF cells, capable of releasing several neurotrophic factors, including Glial-derived neurotrophic factor (GDNF) and Brain-derived neurotrophic factor (BDNF), Vascular endothelial growth factor (VEGF) and Hepatocyte growth factor (HGF), which are critical for the growth, survival and differentiation of developing neurons.

Officers and directors

Irit Arbel Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Chaim Lebovits President
Age: 42
Bio & Compensation  - Reuters
Anthony Fiorino M.D., Ph.D. Chief Executive Officer
Age: 46
Bio & Compensation  - Reuters
Liat Sossover Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Uri Yablonka Chief Operating Officer, Director
Age: 37
Bio & Compensation  - Reuters
Adrian Harel Ph.D. Director - Research and Development
Age: 56
Bio & Compensation  - Reuters
Mordechai Friedman Independent Director
Age: 61
Bio & Compensation  - Reuters
Alon Pinkas Independent Director
Age: 51
Bio & Compensation  - Reuters
Chen Schor CPA Independent Director
Age: 41
Bio & Compensation  - Reuters
Robert G. Shorr Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters